Colesevelam Hydrochloride

CHEMBL1201473 Phase 4 Disetujui Unknown

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

The hydrochloride salt formulation of colesevelam, a non-absorbed bile acid–binding resin used to reduce LDL cholesterol and improve glycemic control in type 2 diabetes. It is taken with meals and does not enter systemic circulation.

Area Terapeutik

Non-Alcoholic Fatty Liver Disease Hyperlipidemia Obesity Type 2 Diabetes Breast Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

The hydrochloride salt formulation of colesevelam, a non-absorbed bile acid–binding resin used to reduce LDL cholesterol and improve glycemic control in type 2 diabetes. It is taken with meals and does not enter systemic circulation.

Yes, Colesevelam Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201473. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Mencari informasi yang ramah bagi pasien?

Colesevelam Hydrochloride di PillFYI

Data Cepat

Sinonim: 1

Tautan Eksternal

ChEMBL CHEMBL1201473

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.